Polaris Group

Equities

6550

KYG7171A1085

Biotechnology & Medical Research

End-of-day quote Taiwan S.E. Other stock markets 06:00:00 2024-05-30 pm EDT			5-day change	1st Jan Change
72 ^TWD	+0.98%		+5.26%	-4.76%

May. 15	Polaris Group Voluntarily Withdraws the Phase III Clinical Trial Protocol for Liver Cancer from the FDA	CI
May. 14	Polaris Group Announces Change of the Member of Compensation Committee	CI

Polaris Group Announces Change of the Member of Compensation Committee

May 14, 2024 at 02:56 am EDT

Polaris Group announced change of the member of Compensation Committee. Name of the previous position holder: K.C. Tsai. Resume of the previous position holder: Chairman of Champion Microelectronic Corp.

Name of the new position holder: Karen Wen. Resume of the new position holder: COO/CSO of Genome Frontier Therapeutics TW Co. Ltd. Reason for the change: by-election of independent director at 2024 Annual General Meeting.

Effective date of the new member: May 14, 2024. The term of the new member of Compensation Committee is same as that of the independent director, until June 11, 2026.

Latest news about Polaris Group

Polaris Group Voluntarily Withdraws the Phase III Clinical Trial Protocol for Liver Cancer from the FDA	May. 15	CI
Polaris Group Announces Change of the Member of Compensation Committee	May. 14	CI
Polaris Group Announces Change of the Member of Audit Committee	May. 03	CI
Polaris Group Announces the Appointment of K Evin Wu	Dec. 21	CI
Polaris Group Announces Chief Executive Officer Changes, Effective December 21, 2023	Dec. 21	CI
Polaris Group agreed to acquire additional unknown stake in Genovior Biotech Corporation for TWD 2 billion.	Dec. 20	CI
Polaris Group Announces First Patient Successfully Dosed with ADI-PEG 20 in Phase II Clinical Trial for NASH at Chang Gung Memorial Hospital, Linkou, Taiwan	Nov. 29	CI
Polaris Group Initiates Rolling Submission of Biologic License Application for ADI-PEG 20 with U.S. FDA to Treat Malignant Pleural Mesothelioma	Nov. 16	CI
Polaris Group Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 10	CI
Polaris Group announced a financing transaction	23-10-05	CI
Polaris Group Appoints K.C. Tsai as Compensation Committee Member	23-09-26	CI
TDW HK Limited announced that it has received $17 million in funding from Polaris Group	23-09-25	CI
Polaris Group Announces Resignation of TAI, JANG-HUEI as Audit Committee and Remuneration Committee Member	23-08-29	CI
Polaris Group Announces of Resignation of TAI, JANG-HUEI as Independent Director	23-08-29	CI
Polaris Group Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Polaris Group Announces Dosing of First Patient in Phase 2 Trial of ADI-PEG 20 with Radiation and TMZ in Patients with GBM	23-08-04	CI
Polaris Group Partners with MatrixCare to Improve MDS Assessment Accuracy for Long-Term Care Communities	23-07-27	CI
Polaris Group Announces MFDS Approves Phase Phase 2 Clinical Protocol Treating GBM with ADI-PEG 20	23-06-27	CI
Polaris Group Appoints Chien-Hsing Chang as Chief Strategy Officer Effective June 20, 2023	23-06-12	CI
Polaris Group Announces Executive Changes Effective June 15, 2023	23-06-12	CI
Polaris Group Announces that TFDA Approves Phase3 Clinical Protocol Treatment HCC with ADI-PEG 20	23-05-30	CI
Polaris Group and Vietnam National Cancer Center Announce the Signing of MOU for Future Collaboration	23-05-29	CI
Polaris Group Submits ADI-PEG 20 to TFDA for INR as Treatment for Hepatocellular Carcinoma	23-05-04	CI
DesigneRx Pharmaceuticals, Inc. announced that it expects to receive $15 million in funding from Polaris Group	23-04-23	CI
Polaris Group Announces the Submission of Polyaris 2020-001 Phase 2 Trial of ADI-PEG 20 to MFDS	23-04-13	CI

Chart Polaris Group

Duration

Period

More charts

Company Profile

Polaris Group is a Cayman Islands-based biopharmaceutical company, which is engaged in advanced therapies, primarily focusing on metabolic related diseases. The Companyâs drug candidate, Pegargiminase (ADI-PEG 20), is advancing through the biologics license applications (BLA) - enabling stage and clinical development. Pegargiminase (ADI PEG 20), is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia and others. Pegargiminase is designed to disrupt cancer cell metabolism, providing a novel approach to treating a range of cancers heavily influenced by metabolic pathways. The Companyâs product pipeline also includes peptide drugs, such as the Semaglutide-related products.

Sector

Biotechnology & Medical Research

Calendar

2024-08-08 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
POLARIS GROUP	-4.76%	1.65B
MODERNA, INC.	+43.36%	54.63B
IQVIA HOLDINGS INC.	-5.31%	39.92B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-11.83%	10.74B

Other Biotechnology & Medical Research